Drug Profile
Research programme: myocardial infarction diagnostic - Alere
Alternative Names: CGEN-144Latest Information Update: 05 Oct 2017
Price :
$50
*
At a glance
- Originator Biosite; Compugen
- Developer Biosite
- Class Antibody diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 29 Sep 2017 Alere has been acquired by Abbott
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction(Diagnosis) in USA (Parenteral)
- 01 Apr 2008 Preclinical trials in Myocardial infarction in USA (Parenteral)